Influence of recombinant codon‐optimized plasmid dna encoding vegf and fgf2 on co‐induction of angiogenesis

Abstract

Several methods for the stimulation of skin wound repair have been proposed over the last few decades. The most promising among them are gene and stem cell therapy. Our present experiments combined several approaches via the application of human umbilical cord blood mononuclear cells (hUCB‐MC) that were transfected with pBud‐VEGF165‐FGF2 plasmid (gene-cell therapy) and direct gene therapy using pBud‐VEGF165‐FGF2 plasmid to enhance healing of full thickness skin wounds in rats. The dual expression cassette plasmid pBud‐VEGF165‐FGF2 en-codes both VEGF and FGF2 therapeutic genes, expressing pro‐angiogenic growth factors. Our results showed that, with two weeks post‐transplantation, some transplanted cells still retained expression of the stem cell and hematopoietic markers C‐kit and CD34. Other transplanted cells were found among keratinocytes, hair follicle cells, endothelial cells, and in the derma. PCNA expression studies revealed that transplantation of transfected cells terminated proliferative processes in regenerating wounds earlier than transplantation of untransfected cells. In the direct gene therapy group, four days post‐operatively, the processes of flap revascularization, while using Easy LDI Microcirculation Camera, was higher than in control wounded skin. We concluded that hUCB‐ MC can be used for the treatment of skin wounds and transfection these cells with VEGF and FGF2 genes enhances their regenerative abilities. We also concluded that the application of pBud‐ VEGF165‐FGF2 plasmids is efficient for the direct gene therapy of skin wounds by stimulation of wound revascularization.